2021年12月31日，回盛生物发布的创业板向不特定对象发行可转换公司债券上市公告书显示，本次发行 可转换公司债券募集资金总额为70,000.00万元(含发行费用)，扣除不含税发行费用的募集资金净额为 68,929.90万元。本次发行可转换公司债券募集资金扣除承销及保荐费855.66万元(不含税)的余额 69,144.34万元已由保荐机构(主承销商)于2021年12月23日汇入公司指定的募集资金专项存储账户中审众 环会计师事务所(特殊普通合伙)已进行验证，并出具了"众环验字(2021)0100097号"《验证报告》。回盛 生物此次的保荐机构(主承销商)为海通证券股份有限公司(现名"国泰海通证券股份有限公司")，保荐代 表人为陈禹安、吴逸。 回盛生物于2020年8月24日在科创板上市，发行数量为2770万股，发行价格33.61元/股，保荐机构(主承 销商)为海通证券股份有限公司(现名"国泰海通证券股份有限公司")，保荐代表人为张若思、金涛。 经计算，回盛生物上述两次募资共计16.31亿元。 中国经济网北京5月28日讯回盛生物（300871）(300871.SZ)近日披露2025年第一季度报告，报告期内， 该公司 ...

Core Points - Mingguan New Materials (688560.SH) reported a significant decline in revenue and net profit for the year 2024, with revenue at 864 million yuan, down 38.13% year-on-year [1] - The company recorded a net loss attributable to shareholders of 67.08 million yuan, compared to a loss of 23.88 million yuan in the previous year [1] - The net cash flow from operating activities was 147 million yuan, a decrease of 30.97% compared to the previous year [1] Financial Performance - Revenue for 2024 was 864 million yuan, down from 1.40 billion yuan in 2023, reflecting a 38.13% decrease [3] - The net profit attributable to shareholders was -67.08 million yuan, compared to -23.88 million yuan in 2023 [3] - The net profit after deducting non-recurring gains and losses was -68.16 million yuan, compared to -35.86 million yuan in the previous year [3] - The net cash flow from operating activities was 146.62 million yuan, down from 212.40 million yuan in 2023, a decline of 30.97% [3] Recent Developments - In Q1 2025, the company reported a revenue of 174 million yuan, a decrease of 46.94% year-on-year [4] - The net profit attributable to shareholders for Q1 2025 was -23.17 million yuan, compared to a profit of 7.93 million yuan in the same period last year [4] - The net cash flow from operating activities for Q1 2025 was -12.90 million yuan, compared to -5.53 million yuan in the previous year [4] Company Background - Mingguan New Materials was listed on the Shanghai Stock Exchange's Sci-Tech Innovation Board on December 24, 2020, with an issue price of 15.87 yuan per share [5] - The total amount raised during the IPO was approximately 651 million yuan, with a net amount of 573 million yuan after expenses [5] - The company planned to use the funds for expanding production capacity in solar battery backplanes and lithium battery aluminum-plastic films, among other projects [5] Capital Raising Activities - In December 2022, the company issued A-shares to specific investors, raising a total of approximately 1.68 billion yuan, with a net amount of about 1.66 billion yuan after expenses [6] - The stock price is currently below the issue price of the recent capital increase [6] - The total amount raised from the two fundraising activities is approximately 2.33 billion yuan [7]

Core Viewpoint - Tianzhihang (688277.SH) announced a share reduction plan involving its major shareholders, the Advanced Manufacturing Fund and the Beijing-Tianjin-Hebei Industrial Collaborative Development Investment Fund, which will collectively reduce their holdings by up to 3% of the company's total shares [1][2][3] Group 1: Share Reduction Plan - The Advanced Manufacturing Fund plans to reduce its holdings by up to 2,263,342 shares (0.50% of total shares) through centralized bidding and up to 4,526,685 shares (1.00% of total shares) through block trading within three months after the announcement [1][2] - The Beijing-Tianjin-Hebei Fund has the same reduction plan as the Advanced Manufacturing Fund, with identical share limits [1][2] - Both funds are classified as concerted actors, holding 21,863,353 shares (4.83%) and 21,866,010 shares (4.83%) respectively, all of which are unrestricted circulating shares [2][3] Group 2: Financial Performance - Tianzhihang has reported continuous losses for five consecutive years, with a net profit attributable to shareholders of -1320.49 million in Q1 2025, compared to -1006.32 million in the same period last year [3] - The company's revenue for 2025 Q1 was 58.58 million, marking a year-on-year increase of 102.40% [3] - Historical revenue figures from 2020 to 2024 show fluctuations, with total revenues of 136 million, 156 million, 156 million, 210 million, and 179 million respectively, while net profits have consistently been negative [3] Group 3: Fundraising Activities - Tianzhihang went public on July 7, 2020, raising a total of 504.48 million, with a net amount of 448.30 million after deducting issuance costs [4] - The company planned to use the raised funds for various projects, including the development of orthopedic surgical robots and marketing system construction [4] - In 2023, Tianzhihang issued 29,545,091 shares at a price of 12.53 yuan per share, raising a total of approximately 370.20 million, with a net amount of 359.76 million after expenses [5][6]

中国经济网北京5月8日讯威腾电气(688226.SH)昨日晚间发布股东询价转让计划书。拟参与威腾电气首 发前股东询价转让(以下简称"本次询价转让")的股东为江苏威腾投资管理有限公司、镇江博爱投资有限 公司。本次询价转让股份的数量为3,253,698股，占总股本的比例为1.73%，转让原因均为自身资金需 求。 威腾电气首次公开发行募集资金总额为2.50亿元，扣除发行费用后，募集资金净额为2.06亿元。威腾电 气最终募集资金净额比原计划少2.00亿元。威腾电气于2021年6月30日披露的招股书显示，公司拟募集 资金4.06亿元，其中，1.63亿元用于母线车间智能化升级改造项目，1.42亿元用于年产2000套智能化中 压成套开关设备及63000台智能型(可通信)低压电器项目，5031.00万元用于研发中心建设项目，5000.00 万元用于补充流动资金。 威腾电气公开发行新股的发行费用合计4450.76万元(不含增值税金额)，其中保荐机构中信证券股份有限 公司获得承销保荐费3000.00万元。 2025年1月7日，威腾电气发布的向特定对象发行A股股票上市公告书显示，本次发行数量30,000,000 股，发行价格19. ...

以下文章来源于解码LP ，作者吴琼 解码LP . 投资界（PEdaily.cn）旗下，专注募资动态 欢迎加入投资界读者群 募资不易。 作者 I 吴琼 报道 I 投资界-解码LP 募资最新一幕。 投资界—解码LP获悉，国家中小企业发展基金有限公司完成第七批第一支子基金签约工 作，即深创投中小企业发展基金（苏州）合伙企业（有限合伙），总规模20亿元。这一 次，深创投为新基金管理人。 放眼创投圈，国家中小企业发展基金向来出手活跃。此次签约拉开第七批子基金序幕， 意味着有望迎来一波密集出资。对于一众苦于募资的GP而言，一场新比拼开始了。 国家级母基金，投了深创投 从过往出资来看，国家中小企业发展基金对GP的遴选颇为严格。印象深刻的是，去年6 月母基金一口气出资6家GP，包括普华资本、基石资本、达晨财智、元璟资本、通和毓 承、国中资本等知名机构。其实这次也并非国家中小企业发展基金首次联手深创投，此 前深创投中小企业发展基金（新疆）有限合伙企业已在新疆乌鲁木齐成立。 时间回到去年7月，国家中小企业发展基金发布第七批子基金管理机构遴选公告，子基金 将通过市场化手段扩大对中小企业的股权投资规模，支持投早投小投创新，重点支持种 ...

Core Points - Gannee Pharmaceutical recently disclosed a significant change in shareholder equity, with Beijing Xute Hongda Technology Co., Ltd. reducing its stake in the company [1][2] - The equity change period was from April 22, 2025, to April 24, 2025, during which Xute Hongda reduced its holdings by 849,822 shares, representing 0.14% of Gannee's total share capital [1][2] - After the change, Xute Hongda holds 40,634,035 shares, accounting for 6.76% of Gannee's total share capital, while its concerted actor, Gan Zhongru, holds 205,643,757 shares, representing 34.21% [1][2] Company Information - Gan Zhongru is the largest shareholder of Gannee Pharmaceutical, while Xute Hongda is the second largest shareholder [2] - Gan Zhongru has been the controlling shareholder and actual controller of Gannee since 2020, serving as the chairman of the company [2] - Gannee Pharmaceutical was listed on the Shanghai Stock Exchange on June 29, 2020, with an initial public offering (IPO) of 40.2 million shares at a price of 63.32 yuan per share [2][3] Fundraising Activities - Gannee Pharmaceutical raised a total of 2.545 billion yuan through its IPO, with a net amount of 2.441 billion yuan after expenses [2][3] - The funds raised were intended for various projects, including marketing network construction and the registration of insulin products in the U.S. [2] - In 2023, Gannee issued 28,508,550 shares at a price of 27.12 yuan per share, raising approximately 773.15 million yuan, with a net amount of about 759.73 million yuan after expenses [3]

Group 1 - The fundraising process involves various combinations of projects and limited partners (LPs) to attract investments [2][3][6] - Investment teams quickly rearrange existing projects to align with the fundraising team's needs, often presenting a different set of projects during fundraising compared to actual investments made later [6][15] - The fundraising team actively seeks out LPs across the country, regardless of the suitability of the LPs, to expand their resource pool [11][12] Group 2 - The key to successful fundraising is having a thick skin and being adaptable to the needs of potential LPs [10][11] - The investment logic is primarily driven by the need to secure fundraising, leading to fragmented investment strategies that may not align with industry resources [15][16] - Institutions are under pressure to provide guarantees on annual returns to LPs due to poor past performance, leading to a focus on projects with acceptable return rates [18]

Core Viewpoint - The company reported a significant decline in both revenue and net profit for the year 2024, indicating potential challenges in its operational performance and market conditions [1][2][3]. Financial Performance - The company achieved operating revenue of 2.005 billion yuan in 2024, a decrease of 39.24% compared to 3.299 billion yuan in 2023 [2][3]. - The net profit attributable to shareholders was 41.11 million yuan, down 92.03% from 515.64 million yuan in the previous year [2][3]. - The net profit after deducting non-recurring gains and losses was -28.13 million yuan, compared to 447.66 million yuan in 2023, reflecting a decline of 106.2% [3]. - The net cash flow from operating activities was 704.67 million yuan, a decrease of 34.26% from 1.072 billion yuan in 2023 [3]. Capital Raising and Stock Issuance - The company was listed on the Sci-Tech Innovation Board on December 30, 2020, raising a total of 2.168 billion yuan through the issuance of 38.71 million shares at a price of 56.00 yuan per share [4]. - The total amount raised from the two fundraising rounds was 7.17 billion yuan [5]. - The company plans to distribute dividends to shareholders, proposing a capital reserve transfer of 4 shares for every 10 shares held and a cash dividend of 10.40 yuan for every 10 shares [5].

Core Insights - The company, Capital Online, reported a revenue of 1.397 billion yuan for the year 2024, representing a year-on-year growth of 12.35% [1][2] - The net profit attributable to shareholders was -303 million yuan, an improvement from -340 million yuan in the previous year, indicating a 10.86% reduction in losses [1][2] - The net cash flow from operating activities reached 241 million yuan, showing a significant increase of 42.51% compared to the previous year [1][2] Financial Performance - Revenue for 2024 was 1,396,789,414.24 yuan, up from 1,243,287,334.15 yuan in 2023 [2] - The net profit attributable to shareholders for 2024 was -303,144,022.54 yuan, compared to -340,078,976.82 yuan in 2023, marking a 10.86% improvement [2] - The net profit after excluding non-recurring gains and losses was -295,912,126.32 yuan for 2024, an improvement from -330,992,782.11 yuan in 2023, reflecting a 10.60% reduction in losses [2] - The net cash flow from operating activities was 240,905,307.74 yuan, up from 169,048,663.77 yuan in 2023, indicating a 42.51% increase [2] Shareholder Metrics - Basic and diluted earnings per share for 2024 were both -0.6126 yuan, an improvement of 15.91% from -0.7285 yuan in 2023 [2] - The weighted average return on equity was -29.90% for 2024, an improvement from -32.75% in 2023 [2] Asset and Equity Position - Total assets at the end of 2024 were 1.955 billion yuan, down 6.24% from 2.085 billion yuan at the end of 2023 [2] - The net assets attributable to shareholders increased to 931 million yuan, up 7.23% from 868 million yuan at the end of 2023 [2] Historical Performance - The company has reported losses for three consecutive years, with net profits attributable to shareholders of -189 million yuan in 2022, -340 million yuan in 2023, and -303 million yuan in 2024 [1][2]

12 月了，各投资人陆续开始年终总结。我也凑个热闹。 回看我的 2024 ，在 lp 爸爸的大力鞭策下，在证监会交易所的严格要求下，我精进迭代了以下六方面的 能力：对赌回购，返投落地，退出，募资， FA ，副业。 每项技能可能还可以再叠加 buff ，输出 plus 技能。 然后，我先默认点进本文的朋友，都已经能比较好理解 lp ，返投， fa 的概念。 技能 1 对赌回购 技能 1+ 无限连带责任 技能 1++ 差异化定价并购退出 作为国资基金，没有对赌回购肯定是不行的。甚至，需要创始人无限连带，只有公司回购都是不足以让 lp 爸爸满意的。 但是，创始人不同意怎么办？ 今年以来，很多上市公司对初创公司的并购，都采用了叫做"差异化定价"的策略。并购的时候，给投资 人高估值，给团队低估值，大家都有了体面。 甚至，再加个拖售权。拖售权 + 差异化定价，即使没有回购，大概率也是能说服投委的。 要么回购，要么拖售权 + 差异化定价，创始人你选一个吧。 "宋总你这谈判策略太强了" 我说：都是合伙人管理有方。 技能 2 返投落地 说的太好了。感谢lp爸爸给我提升的机会。 技能 3 退出 技能 3+ 带年化利率退出 技能 ...